This page shows the SEC filing summaries for Anika Therapeutics, Inc..
Anika Therapeutics, Inc.
CIK: 898437 · 1 filing tracked
Filing History
1
10-K
Annual Report
March 3, 2026
- Strategic pivot via 2024 divestitures to focus on core orthopedic and regenerative medicine franchises.
- Leverages proprietary hyaluronic acid (HA) technology for established viscosupplementation products.
- Strong focus on R&D to expand product pipeline and explore new therapeutic areas.
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.